Valuation: LENSAR, Inc.

Market Cap 85.02M 74.77M 70.71M 64.13M 120M 8.16B 121M 847M 327M 4.16B 319M 312M 13.38B P/E 2026 *
98.3x
P/E 2027 * 115x
Enterprise Value 85.02M 74.77M 70.71M 64.13M 120M 8.16B 121M 847M 327M 4.16B 319M 312M 13.38B EV / Sales 2026 *
1.39x
EV / Sales 2027 * 1.15x
Free-Float
78.48%
Yield 2026 *
-
Yield 2027 * -
1 day-0.58%
1 week-2.69%
Current month-18.00%
1 month-18.68%
3 months+22.20%
6 months+13.34%
Current year-40.84%
1 week 6.79
Extreme 6.79
7.3
1 month 6.79
Extreme 6.79
8.73
Current year 4.95
Extreme 4.95
12.94
1 year 4.95
Extreme 4.95
12.94
3 years 1.8
Extreme 1.8
17.31
5 years 1.8
Extreme 1.8
17.31
10 years 1.8
Extreme 1.8
17.31
Manager TitleAgeSince
Chief Executive Officer 70 2012-01-31
Director of Finance/CFO 52 2026-05-28
Chief Operating Officer 55 2007-12-31
Director TitleAgeSince
Director/Board Member 70 2012-01-31
Chairman 80 2017-11-07
Director/Board Member 78 2018-02-01
Date Insider Type Main position Quantity % Market Cap. Importance
6/3/26 Free

Controller/Auditor

13,066 0.1079%
6/3/26
North Run Capital LP
OtherCompany 0 0% -
6/3/26 Free

Chief Executive Officer

130,662 1.0795%
Change 5-day change 1-year change 3-year change Capi.($)
-0.58%-2.69%-44.29%+121.94% 85.02M
+0.53%+4.17%+46.17%+36.19% 250B
+1.27%+7.33%+22.99%-8.13% 158B
+2.37%+5.46%-5.97%+42.33% 143B
+0.43%+1.78%-55.07%-15.34% 63.65B
+0.63%-1.62%+13.88%+23.85% 49.74B
+1.40%+11.98%+42.00%+58.56% 48.71B
+2.33%+2.38%-14.54%-18.18% 47.94B
+2.17%+5.05%+51.84%+62.64% 42.59B
+0.70%+13.47%+196.54%+103.98% 40.77B
Average +1.31%+3.56%+25.35%+40.78% 84.4B
Weighted average by Cap. +1.29%+4.03%+27.31%+27.15%

Financials

2026 *2027 *
Net sales 61.3M 53.91M 50.98M 46.24M 86.84M 5.88B 87.35M 610M 236M 3B 230M 225M 9.65B 73.9M 65M 61.46M 55.75M 105M 7.09B 105M 736M 284M 3.62B 277M 271M 11.63B
Net income 39.05M 34.34M 32.48M 29.46M 55.32M 3.75B 55.64M 389M 150M 1.91B 147M 143M 6.15B 1.75M 1.54M 1.46M 1.32M 2.48M 168M 2.49M 17.43M 6.73M 85.72M 6.57M 6.43M 275M
Net Debt - -
Logo LENSAR, Inc.
LENSAR, Inc. is a commercial-stage medical device company focused on designing, developing, and marketing advanced systems for the treatment of cataracts and the management of astigmatism as an integral aspect of the procedure. The Company's product portfolio includes the LENSAR Laser System and the ALLY Robotic Cataract Laser System and their associated consumable components. It has developed its ALLY System as a compact, highly ergonomic system utilizing an extremely fast dual-modality laser and integrating artificial intelligence into proprietary imaging and software. ALLY is designed to transform cataract surgery by utilizing its advanced robotic technologies with the ability to perform the entire procedure in a sterile operating room or in-office surgical suite. ALLY allows the surgeon to switch between cataract laser and the surgeon’s existing phacoemulsification device without moving patients from room-to-room. ALLY includes its proprietary Streamline software technology.
Employees
150
Date Price Change Volume
26-09-28 US$6.880 -0.58% 34,769
26-09-25 US$6.920 -2.19% 22,797
26-09-24 US$7.075 -1.05% 17,632
26-09-23 US$7.150 -1.38% 28,275
26-09-22 US$7.250 +0.55% 29,192
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
2
Last Close Price
6.880USD
Average target price
11.50USD
Spread / Average Target
+67.15%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. LNSR Stock